Table 2. Demographics and clinical characteristics of melanoma patients from whom plasma was collected.

Patient case	Sex	Age (years)	Stagea	Previous therapy	Targeted therapyb	Responsec	TTF (days)d
1	F	45	M1c	None	DAB (8) → COMBO	PR	1324
2	F	48	M1c	Fotemustine	DAB	PR	182
3	M	38	M1c	None	DAB	PR	144
4	F	64	M1b	None	COMBO	PR	234
5	M	71	M1c	None	DAB (5) → COMBO	PR	1275
6	M	43	M1c	None	DAB	SD	-
7	M	47	M1c	Fotemustine	DAB	PR	147
8	M	66	M1a	None	DAB (4) → COMBO	CR	488
9	F	82	M1c	Dacarbazine	VEMU	PD	-
10	M	81	M1c	None	VEMU	PD	-
11	M	57	M1c	None	VEMU	PR	223
12	M	60	M1b	None	COMBO	PR	1082
13	M	45	M1c	None	COMBO	PR	188
14	M	70	M1c	None	COMBO	PR	117
15	M	65	M1c	None	VEMU	PD	-
16	M	49	M1c	None	VEMU	PR	147
17	M	39	M1b	None	DAB	PD	-
18	M	81	M1c	None	VEMU	PD	-
19	F	46	M1c	None	COMBO	PR	244
20	M	56	M1c	Nivolumab	COMBO	PR	504
21	M	57	M1c	None	COMBO	PR	172
22	M	35	M1c	None	COMBO	PR	180

^aStage at first plasma collection (i.e. T0).

^bDAB, dabrafenib. In parenthesis, months of monotherapy before trametinib addiction. COMBO, dabrafenib + trametinib. VEMU, vemurafenib.

^cClinical response as evaluated three months after therapy commencement. PR, partial response; SD, stable disease; PD, progressive disease.

^dTTF, time to treatment failure.